{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-004109","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-01-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.062967+00:00","generated_at":"2026-06-20T17:32:15.775199+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Alnylam reports preliminary FY2022 net product revenue of $894M, up 35% YoY","bullets":["ONPATTRO: Q4 $122M, FY $558M; AMVUTTRA: Q4 $69M, FY $94M; combined TTR revenue grew 37% YoY.","GIVLAARI: Q4 $47M, FY $173M (+35% YoY); OXLUMO: Q4 $24M, FY $70M (+17% YoY).","Year-end cash and marketable securities ~$2.2B, down from $2.4B at end 2021.","Over 2,975 patients on commercial TTR drugs and over 520 on GIVLAARI; 280 on OXLUMO as of year-end.","Management cites strong AMVUTTRA launch and reiterates Alnylam P5x25 strategic goals."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-004109","json":"https://secwatch.observer/filing/0001193125-23-004109.json","markdown":"https://secwatch.observer/filing/0001193125-23-004109.md","text":"https://secwatch.observer/filing/0001193125-23-004109.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/0001193125-23-004109-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/d424918d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T17:32:15.775199+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"77ffb692e540914718ab1433c8674147ceee2e42","claim":"ALNYLAM PHARMACEUTICALS, INC. reported fourth quarter and full year 2022 results: revenue approximately $262 million and $894 million, respectively.","evidence_excerpt":"On January 8, 2023, Alnylam Pharmaceuticals, Inc. (the “Company”) announced its preliminary fourth quarter and full year 2022 global net product revenues of approximately $262 million and $894 million, respectively, for ONPATTRO ® (patisiran), AMVUTTRA ® (vutrisiran), GIVLAARI ® (givosiran) and OXLUMO ® (lumasiran), and provided additional updates on the products’ commercial launches.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523004109/0001193125-23-004109-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year 2022"},{"label":"Revenue","value":"approximately $262 million and $894 million, respectively"},{"label":"Result","value":"preliminary results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}